OBJECTIVE: • To determine if combinations of obesity, hypertension and diabetes influence the development of prostate cancer over 15 years of follow-up. PATIENTS AND METHODS: • In 1990, a randomly selected cohort of Caucasian men from Olmsted County, MN, USA, aged 40-79 years, was recruited; 2445 completed a questionnaire that included physician-diagnosed diabetes and hypertension. • Anthropometric measures were collected during clinical examination. Biopsy-confirmed prostate cancer was identified from medical records. • Proportional hazards regression was used to estimate the effects of these metabolic conditions, both individually and in combination, on the incidence rate of prostate cancer. RESULTS: • Men with hypertension alone or in combination with diabetes were more likely to develop prostate cancer than were men without any of the metabolic conditions. • The metabolic syndrome - the presence of all three conditions compared with men with no metabolic components - was only minimally and inversely associated with prostate cancer [hazard ratio (HR): 0.81; 95% confidence interval (CI): 0.20, 3.3] and no monotonic association between the number of metabolic components and prostate cancer was observed. CONCLUSIONS: • Our results suggest that it may not be sufficient to treat metabolic conditions as one variable when investigating the aetiology of prostate cancer in Caucasian men. • Further research should focus on the separate and combined effects of these metabolic conditions in large samples.
OBJECTIVE: • To determine if combinations of obesity, hypertension and diabetes influence the development of prostate cancer over 15 years of follow-up. PATIENTS AND METHODS: • In 1990, a randomly selected cohort of Caucasian men from Olmsted County, MN, USA, aged 40-79 years, was recruited; 2445 completed a questionnaire that included physician-diagnosed diabetes and hypertension. • Anthropometric measures were collected during clinical examination. Biopsy-confirmed prostate cancer was identified from medical records. • Proportional hazards regression was used to estimate the effects of these metabolic conditions, both individually and in combination, on the incidence rate of prostate cancer. RESULTS: • Men with hypertension alone or in combination with diabetes were more likely to develop prostate cancer than were men without any of the metabolic conditions. • The metabolic syndrome - the presence of all three conditions compared with men with no metabolic components - was only minimally and inversely associated with prostate cancer [hazard ratio (HR): 0.81; 95% confidence interval (CI): 0.20, 3.3] and no monotonic association between the number of metabolic components and prostate cancer was observed. CONCLUSIONS: • Our results suggest that it may not be sufficient to treat metabolic conditions as one variable when investigating the aetiology of prostate cancer in Caucasian men. • Further research should focus on the separate and combined effects of these metabolic conditions in large samples.
Authors: S O Andersson; A Wolk; R Bergström; H O Adami; G Engholm; A Englund; O Nyrén Journal: J Natl Cancer Inst Date: 1997-03-05 Impact factor: 13.506
Authors: Carmen Rodriguez; Alpa V Patel; Alison M Mondul; Eric J Jacobs; Michael J Thun; Eugenia E Calle Journal: Am J Epidemiol Date: 2005-01-15 Impact factor: 4.897
Authors: Stephen J Freedland; Elizabeth A Platz; Joseph C Presti; William J Aronson; Christopher L Amling; Christopher J Kane; Martha K Terris Journal: J Urol Date: 2006-02 Impact factor: 7.450
Authors: Jari A Laukkanen; David E Laaksonen; Leo Niskanen; Eero Pukkala; Anna Hakkarainen; Jukka T Salonen Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-10 Impact factor: 4.254
Authors: M Gacci; G I Russo; C De Nunzio; A Sebastianelli; M Salvi; L Vignozzi; A Tubaro; G Morgia; S Serni Journal: Prostate Cancer Prostatic Dis Date: 2017-02-21 Impact factor: 5.554
Authors: Katharine N Sourbeer; Lauren E Howard; Gerald L Andriole; Daniel M Moreira; Ramiro Castro-Santamaria; Stephen J Freedland; Adriana C Vidal Journal: BJU Int Date: 2014-10-20 Impact factor: 5.588
Authors: K Esposito; P Chiodini; A Capuano; G Bellastella; M I Maiorino; E Parretta; A Lenzi; D Giugliano Journal: J Endocrinol Invest Date: 2013-02 Impact factor: 4.256
Authors: Barbra A Dickerman; Johanna E Torfadottir; Unnur A Valdimarsdottir; Kathryn M Wilson; Laufey Steingrimsdottir; Thor Aspelund; Julie L Batista; Katja Fall; Edward Giovannucci; Lara G Sigurdardottir; Laufey Tryggvadottir; Vilmundur Gudnason; Sarah C Markt; Lorelei A Mucci Journal: Int J Cancer Date: 2017-11-16 Impact factor: 7.396
Authors: Francesco Cantiello; Antonio Cicione; Riccardo Autorino; Andrea Salonia; Alberto Briganti; Matteo Ferro; Renato De Domenico; Sisto Perdonà; Rocco Damiano Journal: World J Urol Date: 2013-08-14 Impact factor: 4.226